Hypersensitivity reactions in a mouse model prompted the agency to suspend Denali’s planned Phase I development for DNL952 ...
In early December 2025, Denali Therapeutics announced a US$275 million synthetic royalty funding agreement with Royalty Pharma tied to future worldwide net sales of its investigational Hunter syndrome ...
Zacks Investment Research on MSN
Denali enters into a $275M funding deal with Royalty Pharma
Denali Therapeutics Inc. DNLI has announced a funding agreement with Royalty Pharma plc RPRX for $275 million. The stock ...
The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune ...
Pharmaceutical Technology on MSN
Denali makes $275M funding agreement with Royalty Pharma
Denali has entered a $275m royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa ...
In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...
Recent Performance and Context Denali Therapeutics (DNLI) has quietly put together a strong month, with the stock climbing roughly 33% even as its one year return remains negative. This combination ...
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic ...
Denali Therapeutics and Royalty Pharma entered a $275 million royalty funding agreement based on future sales of tividenofusp alfa.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback